BioSpace News Archive

Auris Medical Holding Ltd. provided an update on its tinnitus drug development strategy.

A truly end-to-end regulatory compliant clinical supply chain solution.

Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, adds J. David Warren, Ph.D., to its Scientific Advisory Board.

Earlier this week, Biogen reported out its first-quarter financial results, showing an 11% increase in revenues, hitting $3.5 billion. But in light of the company’s announcement in late March that it was dropping development of aducanumab for Alzheimer’s, analysts are speculating on what the company needs to do to stay profitable.

The federal anti-kickback statute prevents pharmaceutical companies from providing financial coverage of Medicare copay payments that would encourage patients to purchase a company’s medication.

AstraZeneca reported first-quarter financials, with Product Sales growing 10% (14% at CER) to $5.465 billion. What is more startling, and completely in accordance with the company’s stated goals, Global Oncology sales increased by 54%.

In September 2018 a leap forward in treating burn victims was made with the approval of Avita Medical’s RECELL Autologous Cell Harvesting Device. The Food and Drug Administration (FDA) green lit the California-based company’s burn treatment device that uses a small amount of a patient’s own skin to prepare what is called Spray-On Skin Cells.

We had the opportunity to meet with Arti Dumbrepatil, a postdoctoral fellow in the University of Michigan’s chemistry department. Arti explained her journey as an international student and how a postdoctoral fellowship can prepare you for a career as an independent scientist!

Bringing Attention to Malaria Vaccine Development Efforts

Aqilion searches for early innovative pharmaceutical projects that are based on solid research resting on a firm biological foundation and offering both clinical relevance and patient benefit.